- Home
- IMVT vs HHH Comparison
IMVT vs HHH Comparison
Compare IMVT & HHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- HHH
- Stock Information
- Founded
- IMVT 2018
- HHH 2010
- Country
- IMVT United States
- HHH United States
- Employees
- IMVT N/A
- HHH N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- HHH Real Estate Investment Trusts
- Sector
- IMVT Health Care
- HHH Real Estate
- Exchange
- IMVT Nasdaq
- HHH Nasdaq
- Market Cap
- IMVT 2.8B
- HHH 3.3B
- IPO Year
- IMVT N/A
- HHH N/A
- Fundamental
- Price
- IMVT $15.80
- HHH $69.23
- Analyst Decision
- IMVT Buy
- HHH Buy
- Analyst Count
- IMVT 10
- HHH 2
- Target Price
- IMVT $40.14
- HHH $83.50
- AVG Volume (30 Days)
- IMVT 1.3M
- HHH 453.8K
- Earning Date
- IMVT 08-05-2025
- HHH 07-25-2025
- Dividend Yield
- IMVT N/A
- HHH 5.06%
- EPS Growth
- IMVT N/A
- HHH N/A
- EPS
- IMVT N/A
- HHH 5.22
- Revenue
- IMVT N/A
- HHH $1,793,533,000.00
- Revenue This Year
- IMVT N/A
- HHH N/A
- Revenue Next Year
- IMVT N/A
- HHH $24.62
- P/E Ratio
- IMVT N/A
- HHH $13.25
- Revenue Growth
- IMVT N/A
- HHH 106.40
- 52 Week Low
- IMVT $12.72
- HHH $59.83
- 52 Week High
- IMVT $34.47
- HHH $87.77
- Technical
- Relative Strength Index (RSI)
- IMVT 53.39
- HHH 50.32
- Support Level
- IMVT $15.11
- HHH $69.25
- Resistance Level
- IMVT $17.08
- HHH $71.39
- Average True Range (ATR)
- IMVT 0.76
- HHH 1.24
- MACD
- IMVT -0.00
- HHH 0.09
- Stochastic Oscillator
- IMVT 47.56
- HHH 50.57
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.